Foundayo (Orforglipron): The First Oral GLP-1 Pill

Orforglipron is sold under the brand name Foundayo. Orforglipron is the first oral small-molecule GLP-1 pill, a once-daily, non-peptide GLP-1 receptor agonist from Eli Lilly that the FDA approved in April 2026 for chronic weight management. Its headline feature is delivery: unlike every other approved drug in this class, orforglipron is a tablet you can swallow at any time of day with no food or water restrictions. That makes it different from the weekly injections (semaglutide, tirzepatide) and different from the older oral semaglutide pill (Rybelsus), which is a peptide hobbled by strict empty-stomach timing. For people who would never start a needle, an oral GLP-1 pill changes the math on who actually begins treatment.

This guide explains what orforglipron is, why being a small molecule rather than a peptide matters so much, what the phase 3 program showed for weight loss and blood sugar, how it is dosed, what side effects to expect, and what its manufacturing profile could mean for cost and supply. We are careful with approval status throughout, because the specific indication a drug carries on its label is the difference between what a clinician can legally prescribe and what is still being studied.

What orforglipron is, in plain terms

Orforglipron is a GLP-1 receptor agonist, the same broad family as semaglutide and the GLP-1 half of tirzepatide. It works on the same target: the GLP-1 receptor, which helps coordinate appetite, fullness, and blood sugar. If you want the underlying biology first, our explainer on what GLP-1 is and the overview of the GLP-1 receptor agonist drug class cover how these signals turn into reduced hunger and slower gastric emptying.

The crucial word in orforglipron's description is "small-molecule." Almost every GLP-1 drug to date has been a peptide, a short chain of amino acids engineered to resemble the natural hormone. Peptides are large, fragile molecules. Stomach acid and digestive enzymes tear them apart, which is why semaglutide and tirzepatide are injected: an injection bypasses the gut entirely. Orforglipron is not a peptide. It is a small chemical molecule designed from the ground up to switch on the same receptor while surviving the digestive tract. That single difference is what allows it to work as a simple daily pill.

Orforglipron versus injectable GLP-1s

The injectable GLP-1s set the performance bar. In their pivotal trials, semaglutide produced mean weight loss of roughly 15% and tirzepatide roughly 21%. Orforglipron's trial results land below the strongest injectable, but the comparison is not only about the number on the scale. The route of delivery changes who is willing to start and stay on treatment at all.

For someone deciding between the established injectables, our semaglutide versus tirzepatide comparison is the right starting point. Orforglipron does not necessarily replace those drugs. It widens the menu, especially for people whose main barrier has always been the injection itself.

Orforglipron versus Rybelsus (oral semaglutide)

This is the comparison people get wrong most often, because an oral GLP-1 already exists. Rybelsus is oral semaglutide, and it has been available for years. So why is orforglipron treated as the "first" real oral GLP-1 pill? The answer is again the peptide problem.

Rybelsus is a peptide. To get any of it across the gut wall, it is co-formulated with an absorption enhancer, and even then only a tiny fraction is absorbed. That fragility forces a strict ritual: take it on an empty stomach, with no more than about four ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications. Miss the timing and the dose largely fails to absorb. Orforglipron, as a stable small molecule, has none of those constraints. You take it once a day, food or no food, water or no water, whenever fits your routine. The practical difference between "a pill with rules most people struggle to follow" and "a pill you just take" is large, and it is the reason orforglipron is described as the first truly convenient oral GLP-1.

The phase 3 evidence, and what the label actually says

Orforglipron's approval rests on Lilly's late-stage programme — the weight-management trials under the ATTAIN name, the type 2 diabetes trials under ACHIEVE. Now that the FDA labelling is published, the numbers can be given exactly rather than in ranges.

From the approved prescribing information, both trials ran 72 weeks:

In Trial 1, participants started at a mean weight of about 103 kg and a mean BMI of 37. 71.5% on the top dose lost at least 5% of body weight, against 26.8% on placebo.

A correction to what this page said before. An earlier version of this article described the weight-management results as "low-to-mid teens as a percentage of body weight". That was written before the labelling was public and it overstated the drug. The figure at the maximum dose is 11.1% — meaningful, but below the teens, and well below tirzepatide's roughly 20.9% or semaglutide's roughly 14.9%.

That gap is the honest trade. Orforglipron is a pill you can take with coffee; it is not as powerful as the strongest injection. Anyone choosing between them should know that before, not after. See GLP-1 weight-loss results by drug.

Two caveats apply as they do to every drug in this class. Averages hide wide individual variation, and the weight loss continues only while you keep taking it, because the underlying appetite biology does not change.

How Foundayo is dosed

Once daily, as a tablet, and the labelling is specific. There are six strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg and 17.2 mg.

The titration is slow by design: start at 0.8 mg once daily for at least 30 days, then step up to 2.5 mg, then 5.5 mg, each after a minimum of 30 days, then to 9 mg, 14.5 mg or the 17.2 mg maximum depending on response and tolerability. Reaching the top dose therefore takes at least five months.

The administration instruction is the drug's whole selling point. "Take FOUNDAYO orally once daily, with or without food. Swallow tablets whole. Do not break, crush, or chew." No fasting window, no water rule, no waiting before eating — which is precisely what separates it from Rybelsus.

The slow titration is not a formality. It is the main tool for limiting the gastrointestinal effects below, giving the gut time to adjust before each increase.

The boxed warning

Foundayo carries a boxed warning — the FDA's most serious — for risk of thyroid C-cell tumours, the same one that applies across this drug class. In rodents, GLP-1 receptor agonists produced thyroid C-cell tumours at clinically relevant exposures.

It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC), in anyone with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in anyone with known serious hypersensitivity to orforglipron or its excipients.

Family history matters here, not just your own. It is a question worth asking relatives before your appointment rather than during it.

Side effects, with the actual numbers

The profile is the familiar gastrointestinal one, and the labelling gives the rates. Reactions occurring in at least 5% of treated patients, at the 17.2 mg maximum dose against placebo:

Two things are worth reading off that table. The rates climb with dose — nausea runs 26% at 5.5 mg, 34% at 9 mg and 35% at the maximum — which is the argument for not rushing the titration.

And hair loss is a listed adverse reaction, at 5% against 2% on placebo. It is uncommon, but it is on the label rather than being purely a consequence of rapid weight loss. See why GLP-1 hair loss happens.

The tactics that help with injectable GLP-1s apply to the pill: smaller meals, easing off very greasy food, steady fluids, and not pushing the dose up faster than scheduled. See managing nausea on GLP-1. A pill is not automatically gentler than an injection — the active drug reaches the same receptors.

Why a small molecule matters for cost and supply

Beyond convenience, orforglipron's chemistry has an economic angle. Peptide drugs are complex and relatively expensive to manufacture, and the injectable GLP-1s have repeatedly run into supply shortages as demand outstripped production. A small molecule is a different proposition. Small-molecule tablets are, in general, cheaper and far more scalable to produce than peptides, using manufacturing processes the pharmaceutical industry has refined for decades.

That does not guarantee a low price at launch; what a drug costs a patient depends on the manufacturer's pricing, insurance coverage, and rebates, not just the cost of goods. But the underlying scalability is real, and over time it could ease both supply constraints and price pressure in a category where cost has been a major barrier. For where prices actually sit today across the class, see our GLP-1 cost index for 2026. The potential here is reach: a pill that is cheaper to make and easier to distribute can get to far more people than a refrigerated injectable.

Where orforglipron fits

Orforglipron is best understood as an access drug. It is not the most powerful GLP-1 on weight loss; the strongest injectables and the investigational triple agonists post higher numbers. What it offers is a combination that nothing else in the class has matched: real GLP-1 efficacy in a once-daily pill with no timing rules, from a molecule that is cheaper and easier to make at scale. For the large group of people who will not start injections, or for whom the Rybelsus ritual is unworkable, that combination is the whole point.

A note on indication, because precision matters here. As of 2026, orforglipron is approved for chronic weight management per current labeling. Its status for type 2 diabetes may differ and can change as the regulatory review of the ACHIEVE program proceeds, so do not assume one indication implies the other. Always confirm the current approved use with the prescribing information or a clinician. For the full list of what is cleared in this category, our guide to FDA-approved GLP-1 medications is kept current. Any GLP-1, pill or injection, requires evaluation and a prescription from a licensed clinician or telehealth provider; it is not an over-the-counter product.

Orforglipron's arrival is less about the highest possible weight loss and more about removing the barriers that keep people from starting GLP-1 treatment at all. If an oral GLP-1 sounds like a fit, the practical next step is a conversation with a licensed clinician or telehealth provider who can confirm whether it is medically appropriate for you and what the current approved labeling allows.